Chardan analyst Keay Nakae lowered the firm’s price target on Silence Therapeutics (SLN) to $27 from $35 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q1 report.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLN: